Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found ...

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive ...

The world of oncology is evolving rapidly, with breakthrough technologies transforming the way cancer is treated and managed.

While chemotherapy, radiation and surgeries are common for most cancer treatments, immunotherapy is continuing to allow some ...